Olsen et al listed criteria for therapeutic response in a patient with Mycosis Fungoides or Sezary Syndrome. The response may be measured at various sites, including viscera. The authors are from the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer (EORTC).
Patient selection: following completion of therapeutic regimen
Parameters:
(1) hepatomegaly
(2) splenomegaly
(3) other visceromegaly
(4) organ nodules
Designation
Features
complete response (CR)
all organs involved at baseline are not enlarged on physical exam and imaging studies AND no tumor nodules present AND any mass negative for lymphoma on biopsy
partial response (PR)
(>= 50% regression in nodules OR >= 50% regression in organ size involved at baseline) AND no new sites involved AND no increase in size of any organ or nodule
stable disease (no response, SD)
not meeting criteria for complete response, partial response or progressive disease
progressive disease (PD)
increase by >= 50% of any organ involved at baseline OR new organ involvement OR > 50% in size from the nadir in a patient with partial response (loss of response)
relapse
complete response followed by any new organ involvement
To read more or access our algorithms and calculators, please log in or register.
